在低收入国家优化治疗高级非小细胞肺癌与突变的表皮生长因子受体的治疗:一篇评论
Mousa Alali1, Maher Saifo1,2
1Department of Oncology, Albairouni University Hospital, Faculty of Medicine, Damascus University, Damascus, Syrian Arab Republic.
奥西默提尼布最好用于EGFR突变的晚期非小细胞肺癌 (NSCLC). 第一代和第二代技术知识仍然是可行的选择,特别是在低收入国家无法负担新的治疗.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 医学经济学 医学经济学
背景情况:
- 奥西默提尼布是治疗晚期EGFR突变NSCLC的标准治疗方法.
- 高昂的成本限制了低收入国家对奥西默蒂尼布的获取,这给治疗带来了挑战.
- 制定具有成本效益的治疗计划对于这些人群至关重要.
研究的目的:
- 审查用于高级NSCLC的氨酸激酶抑制剂 (TKI).
- 为叙利亚高级NSCLC患者制定适当的治疗策略.
主要方法:
- 对II期和III期研究进行电子文献搜索.
- 包括2003年1月至2022年5月间发表的研究.
- 专注于EGFR-TKIs在晚期NSCLC中的疗效.
主要成果:
- 审查了17篇文章,比较了各种EGFR-TKI.
- 阿法替尼布和达科米替尼布的无进展和整体存活时间比格菲替尼布更长.
- 奥西默提尼布在对抗T790M突变方面表现出有效性,但作为一线治疗方法的成本效益较低.
结论:
- 奥西默提尼布是EGFR突变高级NSCLC的首选一线治疗方法.
- 第一代和第二代技术知识产权是合适的替代方案,特别是在资源有限的环境中.
- 治疗决策应考虑NSCLC患者的疗效和成本效益.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
相关概念视频
Mitogens and the Cell Cycle
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
